STOCK TITAN

InMed completes Mentari merger; legacy stake about 1%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) completed its merger with Mentari Therapeutics on November 6, 2026, and changed its name to Mentari Therapeutics, Inc. Immediately before closing, Pre-Merger Mentari issued common shares and pre-funded warrants for approximately $490.0 million in gross proceeds, including approximately $52.7 million of convertible-note principal and accrued interest. Former Mentari securityholders held approximately 99.0% of the combined company on a fully diluted basis after closing, compared with approximately 1.0% for former InMed securityholders.

For the three months ended September 30, 2026, Pre-Merger Mentari reported a $32.2 million net loss, versus $6.6 million for the prior-year quarter, and had generated no revenue from product sales. Cash and cash equivalents were $45.8 million as of September 30, 2026. Management said cash and proceeds from the Merger and pre-closing financing were expected to fund operating plans for at least 12 months after the financial statements were issued.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • Major pointPre-closing financing provided approximately $490.0 million in gross proceeds. 57× market cap

Negative

  • Major pointQuarterly net loss was $32.2 million, versus $6.6 million a year earlier.

Filing Explained

Mentari’s July 1 licenses for MT-001 and MT-002 require $10.5 million in unachieved clinical milestones and $10 million on regulatory milestones, plus sales-based royalties. Those payments depend on achieving the milestones; MT-003 remains an option, with up to $12 million in clinical and $10 million in regulatory milestones only if the option is exercised and a license is signed.

Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Pre-closing financing gross proceeds Approximately $490.0 million Financing completed immediately before the November 6, 2026 merger
Quarterly net loss $32.2 million Three months ended September 30, 2026; $6.6 million for the three months ended September 30, 2025
Cash and cash equivalents $45.8 million As of September 30, 2026, for Pre-Merger Mentari
Former Mentari securityholders’ ownership Approximately 99.0% Combined company, fully diluted basis after the merger
Former InMed securityholders’ ownership Approximately 1.0% Combined company, fully diluted basis after the merger
Financing common shares issued 215,042,178 shares Pre-Merger Mentari financing immediately before the merger
Pre-funded warrants issued 7,317,328 warrants Pre-Merger Mentari financing immediately before the merger
PACAP medical
"MT-001 is designed to target PACAP"
CGRP medical
"MT-002, a bispecific product candidate designed to inhibit PACAP and CGRP"
pre-funded warrants financial
"issued common shares and pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Clinical Trial Application regulatory
"filed a Clinical Trial Application in New Zealand for MT-001"
An application submitted to a regulatory authority requesting formal permission to begin testing a new drug, medical device, or treatment in humans. Like asking for a building permit before construction, it summarizes safety data, plans for how the study will be run, and monitoring procedures; investors watch these filings closely because approval lets a program move from lab research to clinical testing, reducing uncertainty and creating value-driving milestones.
Investigational New Drug application regulatory
"anticipated filing an Investigational New Drug application for MT-002"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
Exchange Ratio technical
"based on the Exchange Ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
Net loss $32.2 million Versus $6.6 million for the three months ended September 30, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did INM raise in the Mentari merger financing?

The pre-closing financing had approximately $490.0 million in aggregate gross proceeds immediately before the November 6, 2026 merger. It comprised 215,042,178 common shares and 7,317,328 pre-funded warrants; approximately $52.7 million of the amount represented convertible-note principal and accrued interest.

What was the ownership split after INM merged with Mentari?

Former Mentari securityholders held approximately 99.0% of the combined company on a fully diluted basis, while former InMed securityholders held approximately 1.0%. Approximately 25.7% was attributable to former Mentari securityholders excluding the pre-closing financing, and approximately 73.4% to securities issued in that financing.

When are MT-001 and MT-002 updates expected?

MT-001 is in Phase 1 with dosing ongoing, and initial data are expected in mid-2027. Mentari anticipated filing an IND in the United States or a CTA for MT-002 in the first quarter of 2027, with initial data expected by year-end 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
InMed Pharmaceuticals Inc. NASDAQ false 0001728328 0001728328 2026-11-16 2026-11-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Mentari Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   001-39685   98-1428279

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

221 Crescent Street, Building 23, Suite 105, Waltham, MA   02453
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 887-5080

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   MTRI   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


INTRODUCTORY NOTE

As previously reported, on November 6, 2026 (the “Closing Date”), Mentari Therapeutics, Inc., a Nevada corporation (formerly known as InMed Pharmaceuticals Inc., a British Columbia corporation) (prior to the Closing Date, unless context otherwise requires, “InMed” and, after the Closing Date, the “Company”), consummated the previously announced business combination (the “Merger”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 19, 2026 (as amended), by and among InMed, Indigo Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of InMed, Indigo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of InMed, and Mentari Therapeutics, Inc., a private Delaware corporation (prior to the Closing Date, unless context otherwise requires, “Mentari”). This Current Report on Form 8-K (this “Report”) is being submitted to file (1) the unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto, and (2) Mentari’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2026.

 

Item 2.01.

Completion of Acquisition or Disposition of Assets.

Financial Information

Unaudited Financial Statements

The unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto are attached hereto as Exhibit 99.1 and incorporated herein by reference.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Mentari’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2026 is attached hereto as Exhibit 99.2 and incorporated herein by reference.

Risk Factors

The risks associated with Mentari’s business and operations are described in the Company’s definitive proxy statement/prospectus and management information circular filed on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), which registration statement (File No. 333-297234) was most recently amended on September 29, 2026 and declared effective on October 1, 2026 (the “Proxy Statement/Prospectus”), in the section entitled “Risk Factors—Risks Related to Mentari” beginning on page 84, the risks associated with the Redomestication (as defined in the Proxy Statement/Prospectus) are described in the Proxy Statement/Prospectus in the section entitled “Risk Factors—Risks Related to the Redomestication” beginning on page 122 and the risks associated with the business and operations of the Company are described in the Proxy Statement/Prospectus in the section entitled “Risk Factors—Risks Related to the Combined Company” beginning on page 124, each of which is incorporated herein by reference.

 

Item 2.02.

Results of Operations and Financial Condition.

The information set forth in Item 2.01 and in Exhibits 99.1 and 99.2 to this Report is incorporated into this Item 2.02 by reference.

This Item 2.02 is being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired

The unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and the related notes thereto are attached as Exhibit 99.1 and are incorporated herein by reference. Also included as Exhibit 99.2 and incorporated herein by reference is Mentari’s Management’s Discussion and Analysis for the three and nine months ended September 30, 2026.

 


(d) Exhibits

EXHIBIT INDEX

 

Exhibit No.   

Description

99.1    Unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto.
99.2    Mentari’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2026.
104    Cover page interactive data file (embedded within the inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Mentari Therapeutics, Inc.

(Registrant)

 

Date: November 16, 2026

     

By: /s/ Jerad G. Seurer

 
     

Name: Jerad G. Seurer

 
     

Title: General Counsel and Corporate Secretary

 

Exhibit 99.1

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

   F-1

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and for the three months ended September 30, 2025 and period from June 13, 2025 (Inception) to September 30, 2025

   F-2

Unaudited Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the nine months ended September 30, 2026 and for the period from June 13, 2025 (inception) to September 30, 2025

   F-3

Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and for the period from June 13, 2025 (inception) to September 30, 2025

   F-4

Notes to Unaudited Condensed Consolidated Financial Statements

   F-5


MENTARI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

     September 30,
2026
    December 31,
2025
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 45,791     $ 46,259  

Prepaid expenses and other current assets

     3,393       43  
  

 

 

   

 

 

 

Total current assets

     49,184       46,302  

Other assets (1)

     3,256       —   
  

 

 

   

 

 

 

Total assets

   $ 52,440     $ 46,302  
  

 

 

   

 

 

 

Liabilities, Convertible Preferred Stock and Stockholders’ Deficit

    

Current liabilities

    

Accounts payable

   $ 978     $ 135  

Accrued expenses

     10,473       879  

Related-party accounts payable and accrued expenses

     13,896       9,250  

Related-party common stock warrant liability

     1,062       —   
  

 

 

   

 

 

 

Total current liabilities

     26,409       10,264  

Long term liabilities

    

Accrued interest payable, related party

     2,219       —   

Note payable to related party, noncurrent

     49,980       —   
  

 

 

   

 

 

 

Total liabilities

     78,608       10,264  
  

 

 

   

 

 

 

Commitments and contingencies (Note 11)

    

Convertible preferred stock:

    

Series Seed convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized, issued and outstanding as of September 30, 2026 and December 31, 2025; liquidation preference of $200 as of September 30, 2026 and December 31, 2025

     200       200  

Series A convertible preferred stock, $0.0001 par value; 40,078,699 shares authorized as of September 30, 2026 and December 31, 2025; 40,078,698 shares issued and outstanding as of September 30, 2026 and December 31, 2025; liquidation preference of $55,000 as of September 30, 2026 and December 31, 2025

     54,880       54,880  

Stockholders’ deficit:

    

Common stock, $0.0001 par value; 81,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 5,305,556 shares issued and outstanding as of September 30, 2026 and December 31, 2025

     1       1  

Additional paid-in capital

     1,180       390  

Accumulated deficit

     (82,429 )      (19,433 ) 
  

 

 

   

 

 

 

Total stockholders’ deficit

     (81,248 )      (19,042 ) 
  

 

 

   

 

 

 

Total liabilities, convertible preferred stock and stockholders’ deficit

   $ 52,440     $ 46,302  
  

 

 

   

 

 

 

 

(1)

Includes related party amount of $0.1 million as of September 30, 2026 and $0 as of December 31, 2025.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-1


MENTARI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

     Three Months Ended
September 30, 2026
    Three Months Ended
September 30, 2025
    Nine Months Ended
September 30, 2026
    Period from June 13, 2025
(Inception) to September 30,
2025
 

Operating expenses:

        

Research and development (1)

   $ 28,442     $ 6,101     $ 57,709     $ 6,101  

General and administrative (2)

     2,768       534       4,301       580  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     31,210       6,635       62,010       6,681  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (31,210 )      (6,635 )      (62,010 )      (6,681 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Other income (expense)

        

Interest income

     483       29       1,237       29  

Interest expense (3)

     (1,515 )      —        (2,223 )      —   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     (1,032 )      29       (986 )      29  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (32,242 )    $ (6,606 )    $ (62,996 )    $ (6,652 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (6.39 )    $ (1.32 )    $ (12.56 )    $ (1.33 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average common shares outstanding, basic and diluted

     5,041,931       5,000,000       5,014,131       5,000,000  
  

 

 

   

 

 

   

 

 

   

 

 

 
 
(1)

Includes related party amount of $16.9 million and $30.5 million for the three and nine months ended September 30, 2026, respectively, and $6.1 million and $6.1 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively (see Note 13).

(2)

Includes related party amount of $0.3 million and $0.8 million for the three and nine months ended September 30, 2026, respectively, and $0.4 million and $0.4 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively (see Note 13).

(3)

Includes related party amount of $1.5 million and $2.2 million for the three and nine months ended September 30, 2026 (see Note 13).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-2


MENTARI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

(In thousands, except share amounts)

(Unaudited)

 

    Series Seed Convertible
Preferred Stock
    Series A Convertible
Preferred Stock
    Series Seed Related-party
Subscription Receivable
    Common Stock     Additional     Common Stock Related-party
Subscription Receivable
    Accumulated
Deficit
    Total Stockholders’
Deficit
 
    Shares     Amount     Shares     Amount     Shares     Amount     Paid-in Capital  

Balances as of June 13, 2025 (inception)

    20,000,000     $ 200       —      $ —      $ (200 )      5,000,000     $ 1     $ 49     $ (50 )    $ —      $ —   

Net loss

    —        —        —        —        —        —        —        —        —        (46 )      (46 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balances as of June 30, 2025

    20,000,000     $ 200       —      $ —      $ (200 )      5,000,000     $ 1     $ 49     $ (50 )    $ (46 )    $ (46 ) 

Cash receipts of related-party subscription receivables

    —        —        —        —        200       —        —        —        50       —        50  

Issuance of Series A convertible preferred stock, net of issuance costs

    —        —        40,078,698       54,880       —        —        —        —        —        —        —   

Stock-based compensation expense

    —        —        —        —        —        —        —        8       —        —        8  

Net loss

    —        —        —        —        —        —        —        —        —        (6,606 )      (6,606 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balances as of September 30, 2025

    20,000,000     $ 200       40,078,698     $ 54,880     $ —        5,000,000     $ 1     $ 57     $ —      $ (6,652 )    $ (6,594 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

     Series Seed Convertible
Preferred Stock
     Series A Convertible
Preferred Stock
     Common Stock      Additional
Paid-in Capital
     Accumulated
Deficit
    Total Stockholders’
Deficit
 
     Shares      Amount      Shares      Amount      Shares      Amount  

Balances as of December 31, 2025

     20,000,000        200        40,078,698        54,880        5,305,556        1        390        (19,433 )      (19,042 ) 

Stock-based compensation expense

     —         —         —         —         —         —         8        —        8  

Net loss

     —         —         —         —         —         —         —         (18,206 )      (18,206 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balances as of March 31, 2026

     20,000,000      $ 200        40,078,698      $ 54,880        5,305,556      $ 1      $ 398      $ (37,639 )    $ (37,240 ) 

Stock-based compensation expense

     —         —         —         —         —         —         9        —        9  

Net loss

     —         —         —         —         —         —         —         (12,548 )      (12,548 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balances as of June 30, 2026

     20,000,000      $ 200        40,078,698      $ 54,880        5,305,556      $ 1      $ 407      $ (50,187 )    $ (49,779 ) 

Stock-based compensation expense

     —         —         —         —         —         —         773        —        773  

Net loss

     —         —         —         —         —         —         —         (32,242 )      (32,242 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balances as of September 30, 2026

     20,000,000      $ 200        40,078,698      $ 54,880        5,305,556      $ 1      $ 1,180      $ (82,429 )    $ (81,248 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3


MENTARI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

     Nine Months Ended
September 30, 2026
    Period from June 13,
2025 (Inception) to
September 30, 2025
 

Cash flows from operating activities:

    

Net loss

   $ (62,996 )    $ (6,652 ) 

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

    

Stock-based compensation expense

     1,852       83  

Non-cash interest expense

     4       —   

Changes in operating assets and liabilities:

    

Prepaid expenses and other current assets

     (3,350 )      (21 ) 

Accounts payable

     543       175  

Accrued expenses

     9,141       123  

Related party accounts payable and accrued expenses

     4,614       6,441  

Accrued interest payable, related party

     2,219       —   
  

 

 

   

 

 

 

Net cash (used in) provided by operating activities

     (47,973 )      149  
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock

     —        50  

Proceeds from issuance of Series Seed convertible preferred stock

     —        200  

Proceeds from issuance of Series A convertible preferred stock, net of issuance costs

     —        54,880  

Proceeds from issuance of a related party note payable, net of issuance costs

     49,976       —   

Payment of deferred offering costs (1)

     (2,471 )      —   
  

 

 

   

 

 

 

Net cash provided by financing activities

     47,505       55,130  
  

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

     (468 )      55,279  

Cash and cash equivalents at beginning of period

     46,259       —   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 45,791     $ 55,279  
  

 

 

   

 

 

 

Supplemental disclosures of non-cash financing activities:

    

Deferred offering costs in accounts payable and accrued expenses

   $ 753     $ —   

Deferred offering costs in related party accounts payable and accrued expenses

   $ 32     $ —   

 

(1)

Includes related party amount of $0.1 million for the nine months ended September 30, 2026.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4


1. Nature of the Business and Basis of Presentation

Background and Basis of Presentation

Mentari Therapeutics, Inc. (“Mentari” or the “Company”) was established and incorporated under the laws of the state of Delaware on June 13, 2025. Mentari is a clinical-stage biotechnology company developing therapies for the prevention of migraine. Mentari’s pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient, infrequent subcutaneous dosing, MT-002, an anti-PACAP and anti-CGRP bispecific antibody designed to inhibit these complementary pathways, MT-003, an anti-CGRP half-life extended antibody, and MT-004 and MT-005, antibodies directed at novel, undisclosed targets for migraine. The Company was founded by healthcare investor Fairmount Funds Management LLC (“Fairmount”) and launched to research and develop antibody candidates licensed from Paragon Therapeutics, Inc. (“Paragon”). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities.

The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.

The Company’s potential product candidates will require approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company’s potential product candidates will receive all the required approvals. In addition, there can be no assurance that the Company’s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all.

On May 19, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization with InMed Pharmaceuticals Inc. (“InMed”) and Indigo Merger Sub Corp. (“First Merger Sub”) and Indigo Merger Sub II, LLC (“Second Merger Sub”), both wholly owned subsidiaries of InMed, which was subsequently amended on July 6, 2026 (as amended, the “Merger Agreement”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub merged with and into Mentari, with Mentari continuing as a wholly owned subsidiary of InMed and the surviving corporation (the “First Merger”). Immediately following the First Merger and as part of the same overall transaction, Mentari merged with and into Second Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”), with Second Merger Sub being the surviving entity of the Second Merger. The Merger closed on November 6, 2026, following the effectiveness of InMed’s registration statement on Form S-4 and receipt of approval by the stockholders of each of Mentari and InMed. In connection with the Merger, Second Merger Sub changed its corporate name to “Mentari Therapeutics Operating Company LLC” and InMed changed its name to “Mentari Therapeutics, Inc.” InMed following the Merger is referred to herein as the “Combined Company.” The Combined Company is led by the Company’s management team and remains focused on developing therapies for migraine prevention.

In connection with the Merger, on May 19, 2026, the Company entered into a securities purchase agreement (as amended on July 22, 2026, the “Securities Purchase Agreement”) with certain institutional and accredited investors, pursuant to which such investors agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of the Merger, shares of Mentari common stock and pre-funded warrants at a purchase price of $1.8928 per share and $1.8927 per warrant, for an aggregate purchase price of $290.0 million in a private placement (the “First Pre-Closing Financing”), which includes approximately $52.7 million of principal and accrued interest under the Convertible Note (see Note 5), which was contributed as consideration in the First Pre-Closing Financing. On July 22, 2026, the Company amended the Securities Purchase Agreement, pursuant to which certain institutional and accredited investors agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-5


the Merger and concurrently with the First Pre-Closing Financing, additional shares of Mentari common stock and pre-funded warrants at a purchase price of $2.8923 per share and $2.8922 per warrant, for an aggregate purchase price of $200.0 million in a private placement (the “Second Pre-Closing Financing” and, together with the First Pre-Closing Financing, the “Mentari Pre-Closing Financing”). The Mentari Pre-Closing Financing was conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and occurred immediately prior to the closing of the Merger. Shares of the Company’s common stock and pre-funded warrants to purchase shares of the Company’s common stock issued pursuant to the Mentari Pre-Closing Financing were converted into shares of InMed common stock and pre-funded warrants to purchase shares of InMed common stock in accordance with the exchange ratio set forth in the Merger Agreement at the effective time of the First Merger. Refer to Note 15 for subsequent events related to the closing of the Merger and related transactions on November 6, 2026. On November 4, 2026, prior to the consummation of the Merger, InMed effected a one-for-ten reverse stock split of its common stock (the “Reverse Stock Split”).

The accompanying unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission regarding interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position and the results of its operations for the interim periods presented. The balance sheet as of December 31, 2025 was derived from audited financial statements as of that date. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026 or any other interim period or for any future year.

The unaudited condensed consolidated financial statements include accounts of the Company and its wholly owned subsidiary Mentari Securities Corporation established in January 2026. All intercompany amounts are eliminated in consolidation.

Going Concern

The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within twelve months of the date that the unaudited condensed consolidated financial statements are issued.

Since its inception, the Company has devoted substantially all of its resources to advancing the development of its programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.

As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its potential product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.

If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company’s business, financial condition, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that may result if the Company is not able to continue as a going concern.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-6


The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred net losses of $32.2 million and $63.0 million for the three and nine months ended September 30, 2026, respectively, and had an accumulated deficit of $82.4 million as of September 30, 2026. As of September 30, 2026, the Company had $45.8 million in cash and cash equivalents.

The Company’s management expects that the existing cash and cash equivalents that were primarily raised from Series Seed and Series A convertible preferred stock financings and the issuance of convertible notes, together with proceeds received from the closing of the Merger and Mentari Pre-Closing Financing on November 6, 2026 (see Note 15), will be sufficient to fund the Company’s operating plans for at least twelve months from the date these unaudited condensed consolidated financial statements are issued.

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are detailed in the Note titled “2. Summary of Significant Accounting Policies” of the Company’s December 31, 2025 audited financial statements and the related notes included in InMed’s Registration Statement on Form S-4 most recently amended on September 29, 2026 and declared effective on October 1, 2026. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies except as noted below.

Use of Estimates

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these unaudited condensed consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.

Deferred Offering Costs

The Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After the consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. As of September 30, 2026, deferred offering costs of $3.3 million were recorded as Other Assets in the unaudited condensed consolidated balance sheets.

Note Payable to Related Party

The Company accounts for its convertible note at amortized cost. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible note using the effective interest method and are accounted for as interest expense within the Company’s consolidated statements of operations and comprehensive loss (see Note 5).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-7


Stock-Based Compensation

During the three months ended September 30, 2026, the Company began issuing stock options in addition to its existing restricted stock awards (“RSAs”). The Company measures stock options at their grant-date fair value using the Black-Scholes option-pricing model, which incorporates assumptions regarding expected volatility, expected term, risk-free interest rate and expected dividend yield. Compensation expense for stock options with service-based vesting conditions is recognized on a straight-line basis over the requisite service period, generally the vesting period of the respective awards. Forfeitures are accounted for as they occur (see Note 8).

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). The amendments in ASU 2024-03 require public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company’s annual reporting period beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its unaudited condensed consolidated financial statements.

3. Fair Value of Financial Instruments

The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during the periods presented. The following table sets forth the Company’s financial assets carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September 30, 2026 and December 31, 2025 (in thousands):

 

     September 30, 2026  
     Level 1      Level 2      Level 3      Total  

Assets:

           

Money market funds

   $  43,913      $  —       $ —       $  43,913  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

   $ 43,913      $ —       $  —       $ 43,913  
  

 

 

    

 

 

    

 

 

    

 

 

 
     December 31, 2025  
     Level 1      Level 2      Level 3      Total  

Assets:

           

Money market funds

   $ 44,825      $ —       $ —       $ 44,825  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

   $ 44,825      $ —       $ —       $ 44,825  
  

 

 

    

 

 

    

 

 

    

 

 

 

Cash equivalents consist of money market funds, which were valued by the Company based on quoted market prices, which represents a Level 1 measurement within the fair value hierarchy.

4. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

 

     September 30,      December 31,  
     2026      2025  

Accrued research and development

   $ 9,123      $  691  

Accrued professional and consulting fees

     1,195        188  

Accrued employee compensation and benefits

     155        —   
  

 

 

    

 

 

 

Total

   $  10,473      $ 879  
  

 

 

    

 

 

 

5. Note Payable with Related Party

In May 2026, the Company entered into a Convertible Note Purchase Agreement (the “Note Purchase Agreement”) with Fairmount Healthcare Fund II, L.P. (“Fairmount Fund II”), an affiliate fund of Fairmount, which is considered a related party (see Note 13), whereby the Company issued a convertible note (the “Convertible Note”), with an initial principal amount of $50.0 million that accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on June 30, 2028 (the

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-8


“Maturity Date”). Prepayment is not permitted without prior written consent from Fairmount. Pursuant to the Note Purchase Agreement, the Company has the right to issue additional convertible notes up to an aggregate principal amount equal to $20.0 million to Fairmount Fund II. As of September 30, 2026, the Company had outstanding borrowings of $50.0 million from Fairmount Fund II under its Convertible Note.

Upon the occurrence of the Mentari Pre-Closing Financing (see Note 1), which qualifies as a “Next Equity Financing” under the Convertible Note, the principal amount and all accrued interest under the Convertible Note will convert into a number of shares of Mentari preferred stock or common stock, as the case may be, equal to the quotient obtained by dividing the principal amount of the Convertible Note and accrued interest thereon by the price per share paid by the investors in the Mentari Pre-Closing Financing. In the event of a Corporate Transaction, as defined in the Convertible Note, the principal amount of the Convertible Note and accrued interest thereon will convert into a number of shares based on the Company’s Valuation and Fully-Diluted Capitalization, as defined in the Convertible Note, immediately prior to the closing of the Corporate Transaction.

The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation and separate accounting, and no such terms or features were identified.

The Company paid debt issuance costs of less than $0.1 million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of the Convertible Note on the unaudited condensed consolidated balance sheets and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the three and nine months ended September 30, 2026, the Company recognized interest expense related to the Convertible Note of $1.5 million and $2.2 million, respectively, which included non-cash interest expense related to the amortization of debt issuance costs of less than $0.1 million. The weighted average effective interest rate of the Convertible Note was approximately 12.0%.

6. Convertible Preferred Stock

On June 13, 2025, the Company issued 20,000,000 shares of the Series Seed Convertible Preferred Stock to Fairmount Fund II, at a purchase price of $0.01 per share for gross proceeds of $0.2 million.

On September 18, 2025, the Company entered into a Series A Preferred Stock Purchase Agreement to issue certain investors shares of Series A Convertible Preferred Stock, $0.0001 par value per share, at a purchase price of $1.3723 per share. The Company issued a total of 40,078,698 shares of the Series A Convertible Preferred Stock to Fairmount Fund II, as well as certain other investors for gross proceeds of $55.0 million. Of the 40,078,698 shares of Series A Convertible Preferred Stock issued, 7,287,036 shares of Series A Convertible Preferred Stock were issued to Fairmount Fund II.

Upon the issuance of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features as embedded derivatives.

The holders of the Convertible Preferred Stock have the following rights and preferences:

Voting

The holders of Convertible Preferred Stock are entitled to vote, together with the holders of the Company’s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-9


In addition, the holders of shares of Series Seed Preferred Stock, voting together exclusively and as a separate class on an as converted to Common Stock basis, are entitled to elect two directors of the Company. The holders of shares of common stock and any other class or series of voting stock (including Series A Convertible Preferred Stock), exclusively and voting together as a single class on an as converted to Common Stock basis, are entitled to elect the balance of the total number of directors of the Company.

Conversion

Each share of Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. Additionally, in the event of a Mandatory Conversion, as defined in the Company’s certificate of incorporation, each share of Series A Convertible Preferred Stock will be automatically converted into shares of common stock and each share of Series Seed Convertible Preferred Stock will be automatically converted into shares of non-voting preferred stock at the applicable conversion ratio then in effect upon (i) the closing of a firm-commitment underwritten public offering of the Company’s common stock, (ii) the closing of any business combination pursuant to which the Company is merged into, or otherwise combined with, a public company listed on a national securities exchange, and (iii) the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class. The rights, privileges, duties and obligations relating to the non-voting preferred stock are to be determined at the time of a Mandatory Conversion.

The conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.01 per share for Series Seed Preferred Stock and the original issue price is $1.3723 per share of Series A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company’s certificate of incorporation, as amended and restated). As of September 30, 2026, the conversion price was $0.01 per share for Series Seed Preferred Stock and the conversion price was $1.3723 per share of Series A Preferred Stock. As of September 30, 2026 and December 31, 2025, each outstanding share of Convertible Preferred Stock was convertible into common stock on a one-for-one basis.

Dividends

The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred Stock in an amount at least equal to (i) in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii) in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based on the respective Original Issue Price of Series A Convertible Preferred Stock and Series Seed Convertible Preferred Stock. Since inception of the Company, no dividends have been declared or paid by the Company.

Liquidation

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of (i) the applicable original issue price per share of the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-10


Unless the holders of a majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets.

Redemption

The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.

7. Common Stock

As of September 30, 2026 and December 31, 2025, the Company had the authority to issue a total of 81,000,000 shares of common stock at a par value of $0.0001 per share. As of September 30, 2026 and December 31, 2025, 5,000,000 shares of common stock were issued and outstanding and 305,556 RSAs were issued and outstanding. Each share of common stock entitles the holder to one vote, together with the holders of any other class or series of voting stock (including Convertible Preferred Stock), on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company’s board of directors (the “Board of Directors”), subject to the preferential dividend rights of the holders of Convertible Preferred Stock.

As of September 30, 2026 and December 31, 2025, shares of common stock reserved for issuance consist of the following:

 

     September 30,      December 31,  
     2026      2025  

Convertible Preferred Stock

     60,078,698        60,078,698  

Stock Options

     11,773,692        —   

Warrants

     1,237,430        653,842  
  

 

 

    

 

 

 

Total shares of common stock reserved for issuance

     73,089,820        60,732,540  
  

 

 

    

 

 

 

8. Stock-Based Compensation

2025 Equity Incentive Plan

On August 13, 2025, the Board of Directors approved the 2025 Equity Incentive Plan (the “2025 Plan”), under which the Company may grant stock options, restricted stock awards (“RSAs”), restricted stock units, or other stock-based awards to employees, officers, directors, consultants, entities, and advisors. The 2025 Plan is administered by the Board of Directors, or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Upon adoption, the 2025 Plan authorized 2,777,778 shares of common stock reserved for issuance under the plan. On September 18, 2025, the 2025 Plan was amended to increase the number of shares of common stock reserved for issuance by 9,301,470 shares. As of September 30, 2026, the total number of shares of common stock reserved for issuance under the 2025 Plan was 12,079,248, with no shares of common stock available for future grants.

Stock Option Valuation

The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option- pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-11


vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.

The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the nine months ended September 30, 2026:

 

     Nine months ended
September 30, 2026
 

Weighted average expected term (years)

     6.1  

Weighted average expected volatility

     87.7 % 

Risk-free interest rate

     5.0 % 

Dividend yield

     0.0 % 

Stock Options

The following table summarizes the stock option activity for the nine months ended September 30, 2026:

 

     Number of Options      Weighted Average Exercise
Price
     Weighted Average
Remaining Contractual
Term (Years)
     Aggregate Intrinsic
Value (thousands)
 

Outstanding balance as of December 31, 2025

     —       $ —         —       $  —   

Granted

     11,773,692        2.06        
  

 

 

          

Outstanding balance as of September 30, 2026

     11,773,692      $  2.06        10.0      $ 275  
  

 

 

          

Vested and expected to vest, September 30, 2026

     11,773,692      $ 2.06        10.0      $ 275  
  

 

 

          

Exercisable as of September 30, 2026

     25,000      $ 1.12        9.8      $ 32  
  

 

 

          

The weighted average grant-date fair value of stock options granted for the three and nine months ended September 30, 2026 was $1.57. For the nine months ended September 30, 2026, there was $0.3 million intrinsic value related to outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had an exercise price lower than the fair value of the Company’s common stock. There were no stock options granted during the period from June 13, 2025 (inception) to September 30, 2025.

Restricted Stock Awards

The following table summarizes the RSA activity for the nine months ended September 30, 2026:

 

     Number of RSAs      Weighted Average Grant
Date Fair Value
 

Unvested balance as of December 31, 2025

     305,556      $  0.46  

Granted

     —         —   

Vested

     (82,755 )       0.46  

Forfeited

     —         —   
  

 

 

    

 

 

 

Unvested balance as of September 30, 2026

     222,801      $ 0.46  
  

 

 

    

 

 

 

As of September 30, 2026, 222,801 RSAs were outstanding and unvested. The outstanding and unvested RSAs were granted at an estimated fair value of $0.46 per share. Such RSAs have service-based vesting conditions only and vest over a four-year period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder’s service with the Company voluntarily or involuntarily terminates.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-12


Paratari Warrant Obligation

In September 2025, the Company entered into the Antibody Discovery and Option Agreement (the “Paragon Option Agreement”) with Paragon and Paratari, an entity formed by Paragon as a vehicle to hold equity in the Company. Under the terms of the Paragon Option Agreement, Paratari is entitled to grants of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company’s common stock, on a fully diluted basis, on December 31, 2025 and December 31, 2026, with an exercise price equal to the fair market value of the underlying shares of the Company’s common stock (the “Paratari Warrant Obligation”). If the term with respect to all Research Programs ends prior to the end of a calendar year, the warrant for such calendar year shall be pro-rated for that calendar year. The grant dates for the issuance of warrants were expected to be December 31, 2025 and December 31, 2026 (if the term with respect to all Research Programs is still active), respectively, as all terms of the award, including number of shares and exercise price, will be known by all parties by this date. Paratari’s research and discovery related activities have a service inception date preceding the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, the Company records a liability for the warrants expected to be granted to Paratari as the related services are being provided, with the value of the liability based on the estimated fair value of the warrants at each interim reporting date.

On December 31, 2025, the fair value of the December 31, 2025 Paratari Warrant Obligation of $0.3 million was reclassified from liability to equity when the Company settled its 2025 obligations under the Paratari Warrant Obligation by issuing Paratari a warrant to purchase 653,842 shares of the Company’s common stock at an exercise price of $0.58 per share. The warrant has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of September 30, 2026, the warrant issued under the Paratari Warrant Obligation is outstanding and unexercised.

As of September 30, 2026, the estimated fair value of the warrant to be granted on December 31, 2026 was approximately $1.4 million. For the three and nine months ended September 30, 2026, $0.7 million and $1.1 million were recognized as stock-based compensation expense, respectively, related to the December 31, 2026 Paratari Warrant Obligation in the unaudited condensed consolidated statements of operations and comprehensive loss. No stock-based compensation expense was recognized related to the December 31, 2026 Paratari Warrant Obligation for the period from June 13, 2025 (inception) to September 30, 2025. As of September 30, 2026, there was approximately $0.3 million in unamortized expense related to the December 31, 2026 Paratari Warrant Obligation.

Stock-Based Compensation Expense

The following table summarizes the classification of the Company’s stock-based compensation expense in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
     Nine Months Ended
September 30, 2026
     Period from June 13, 2025
(Inception) to
September 30, 2025
 

General and administrative

   $ 592      $ 8      $ 609      $ 8  

Research and development

     923        75        1,243        75  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 1,515      $ 83      $ 1,852      $ 83  
  

 

 

    

 

 

    

 

 

    

 

 

 

As of September 30, 2026, total unrecognized compensation cost related to the stock options was $17.7 million, which is expected to be recognized over a weighted average period of 3.8 years. As of September 30, 2026, total unrecognized compensation cost related to the unvested RSAs was $0.1 million, which is expected to be recognized over a weighted average period of 2.9 years.

The following table summarizes the award types of the Company’s stock-based compensation expense in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

RSAs

   $ 9      $ 8      $ 26      $ 8  

Stock Options

     764        —         764        —   

Paratari Warrant Obligation

     742        75        1,062        75  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 1,515      $ 83      $ 1,852      $ 83  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-13


9. Income Taxes

No provision for income taxes was recorded for the three and nine months ended September 30, 2026 or for the three months ended September 30, 2025 and the period from June 13, 2025 (inception) to September 30, 2025. Deferred tax assets generated from the Company’s net operating losses and capitalized research and development have been fully reserved for, as the Company believes it is not more likely than not that the benefit will be realized due to the Company’s cumulative losses to date.

10. Paragon Option Agreements

Antibody Discovery and Option Agreement

In September 2025, the Company entered into the Paragon Option Agreement for two research programs: MT-001, a monospecific Anti-PACAP antibody, and MT-002, a bispecific Anti-PACAP and CGRP antibody. Under the Paragon Option Agreement, the Company has the exclusive option (an “Option”), on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms to further develop, manufacture and commercialize the resulting antibody (a “License Agreement”). If the Company exercises its options and finalizes the related license agreements, it will be required to make non-refundable milestone payments to Paragon of up to $12.0 million upon the achievement of certain clinical development milestones and up to $10.0 million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each developed product.

Under the terms of the agreement, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to the Company (each, a “Research Program”) and certain administrative activities. The Paragon Option Agreement requires the Company, Paragon, and Paratari to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a “Research Plan”). Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed upon budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from the Company and two employees from Paragon, with the Company and Paragon each having one vote with respect to decisions of the committee. When Paragon and Paratari have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Paratari will deliver to the Company a data package that includes sequence information for all then-existing project antibodies and results.

Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the later of: (i) the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii) if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii) the expiration of the applicable Research Term (as defined under the Paragon Option Agreements). The Company may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30 days’ prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i) 30 days’ prior written notice of the other party’s material breach that remains uncured for the 30-day period and (ii) the other party’s bankruptcy.

Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-14


no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. Further, under a License Agreement, the Company would also be required to make royalty payments to Paragon in the low-to-mid single-digit percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.

Additionally, as part of the Paragon Option Agreement, on each of December 31, 2025 and December 31, 2026 (if the term with respect to all Research Programs is still active), the Company will grant Paratari warrants to purchase a number of shares equal to 1.00% of the Company’s then outstanding common stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of the Company’s common stock on each respective grant date. If the term with respect to all Research Programs ends prior to the end of a calendar year, the warrant for such calendar year shall be pro-rated for that calendar year (see Note 8).

The Company concluded that the rights obtained under the Paragon Option Agreement represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with no alternative future use. The Paragon Option Agreement did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the in-process research and development assets, which represent a group of similar identifiable assets. All the upfront consideration to cover the cost of development work by Paragon prior to the effective date paid by Mentari (“Pre-effective Date Development Costs”) was allocated to the in-process research and development assets acquired and immediately expensed as part of research and development expenses on the unaudited condensed consolidated statement of operations and comprehensive loss. In addition, on a research program-by-research program basis, the Company is required to pay a one-time, non-refundable Research Initiation Fee for the finalization of the Research Plan for each respective research program that is also expensed immediately as part of research and development expense. Amounts paid for on-going development costs, monthly development fees and additional expenses incurred by Paragon are recognized as research and development expense when incurred. Amounts paid as reimbursements for administrative activities incurred by Paragon are recognized as general and administrative expense when incurred.

On July 1, 2026, the Company entered into a License Agreement with Paragon for MT-001 and MT-002 (the “License Agreement”). Under the License Agreement the Company is required to pay $10.5 million of certain clinical development milestones that were not yet achieved under the Paragon Option Agreement and $10.0 million upon the achievement of certain regulatory milestones, as well as tiered royalty payments for both MT-001 and MT-002.

On July 1, 2026, the Company amended the Paragon Option Agreement to add MT-003, an anti-CGRP half-life extended antibody. Under this amendment, the Company has an Option to enter into a License Agreement for MT-003 with Paragon consistent with a set of pre-negotiated terms to further develop, manufacture and commercialize the resulting antibody. If the Company exercises its option and finalizes the related license agreement, it will be required to make non-refundable milestone payments to Paragon of up to $12 million upon the achievement of certain clinical development milestones and up to $10 million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of the product. The Company is required to reimburse Paragon for $0.1 million of Pre-effective Date Development Costs. The Company paid $0.1 million to Paragon for pre-effective costs related to MT-003 in July 2026.

On July 1, 2026, the Company entered into a separate Antibody Discovery and Option Agreement with Paragon Laboratories, Inc. (“Paragon Labs”) for MT-004 and MT-005, antibodies directed at novel, undisclosed targets for migraine. Paragon Labs is controlled by Fairmount and is a related party to the Company. Under this option agreement, the Company has an Option, on a Research Program-by-Research Program basis, to enter into a License Agreement with Paragon Labs consistent with a set of pre-negotiated terms to further develop, manufacture and commercialize the resulting antibodies. If the Company exercises its options and finalizes the related license agreements, it will be required to make non-refundable milestone payments to Paragon Labs of up to $12.0 million upon the achievement of certain clinical development

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-15


milestones and up to $10.0 million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each developed product. The Company is required to reimburse Paragon Labs for $1.0 million and $1.5 million of Pre-effective Date Development Costs for MT-004 and MT-005, respectively. The Company paid $1.0 million and $1.5 million to Paragon for pre-effective costs related to MT-004 and MT-005, respectively, in July 2026.

The following table summarizes the expense recorded under the Paragon Option Agreements in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
     Nine Months Ended
September 30, 2026
     Period from June 13, 2025
(Inception) to
September 30, 2025
 

Research and development

   $ 16,048      $ 6,025      $ 29,249      $ 6,025  

General and administrative

     252        416        738        416  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 16,300      $ 6,441      $ 29,987      $ 6,441  
  

 

 

    

 

 

    

 

 

    

 

 

 

As of September 30, 2026 and December 31, 2025, $13.8 million and $9.3 million, respectively, were due to Paragon and included in related party accounts payable and accrued expenses in the Company’s unaudited condensed consolidated balance sheets.

11. Commitments and Contingencies

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its director and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its unaudited condensed consolidated financial statements as of September 30, 2026 or December 31, 2025.

Legal Proceedings

From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of September 30, 2026 and December 31, 2025, the Company was not a party to any material legal proceedings or claims.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-16


12. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

Numerator:

           

Net loss

   $ (32,242 )     $ (6,606 )     $ (62,996 )     $ (6,652 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average common shares outstanding,
basic and diluted

     5,041,931        5,000,000        5,014,131        5,000,000  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss per share attributable to common stockholders,
basic and diluted

     (6.39 )       (1.32 )       (12.56 )     $ (1.33 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

For the computation of basic net loss per share attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect:

 

     September 30, 2026      September 30, 2025  

Convertible preferred stock (as converted to common stock)

     60,078,698        60,078,698  

Unvested restricted stock awards

     222,801        505,556  

Stock Options

     11,773,692        —   

Warrants

     653,842        —   
  

 

 

    

 

 

 

Total

     72,729,033        60,584,254  

13. Related Party Transactions

Fairmount, Paragon, and Paratari have been identified as related parties and have engaged in material transactions with the Company. As of September 30, 2026, Fairmount, Paragon, and Paratari owned approximately 41.7%, 3.8%, and 3.8% respectively, of the outstanding shares of stock in the Company, assuming the conversion of preferred stock into common stock. Fairmount currently has two representatives appointed to the Company’s Board of Directors. Fairmount appointed Paragon’s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. The Company entered into significant related party transactions with Fairmount, Paragon, Paragon Labs and Paratari during 2025 and 2026 related to the issuance of a Convertible Note to Fairmount (see Note 5), the issuance of Convertible Preferred Stock to Fairmount (see Note 6), the issuance of RSAs to employees of Fairmount, the issuance of warrants to Paratari (see Note 8), Paragon Option Agreement (see Note 10), and Antibody Discovery and Option Agreement with Paragon Labs (see Note 10).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-17


The following is a summary of related party accounts payable and accrued expenses, related party common stock warrant liability, and related party noncurrent liability (in thousands):

 

     September 30, 2026      December 31, 2025  

Paragon reimbursable Option Agreement fees

   $ 13,528      $ 9,245  

Paragon reimbursable company start-up fees

     283        5  

Fairmount reimbursable consulting fees

     85        —   
  

 

 

    

 

 

 

Total related party accounts payable and accrued expenses

   $ 13,896      $ 9,250  
  

 

 

    

 

 

 

Paratari Warrant Obligation

   $ 1,062      $ —   
  

 

 

    

 

 

 

Total related party common stock warrant liability

   $ 1,062      $ —   
  

 

 

    

 

 

 

Accrued interest payable, related party

   $ 2,219      $ —   

Note payable to related party, noncurrent

     49,980        —   
  

 

 

    

 

 

 

Total related party noncurrent liability

   $ 52,199      $ —   
  

 

 

    

 

 

 

14. Segment Reporting

The Company has one reportable segment relating to the research and development of its research programs. The Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, manages the Company’s operations on a company-wide basis for the allocation of resources and the assessment of performance. The Company’s measure of segment profit or loss used to assess performance and allocate resources is net loss. The CODM uses net loss to evaluate losses generated from the Company’s business activities in deciding how to allocate company resources and in monitoring budget versus actual results. Assets are also managed on a company-wide basis. The measure of segment assets is reported on the consolidated balance sheets as total assets.

The table below is a summary of the segment loss, including significant segment expenses that are reviewed by the CODM (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

Operating expenses and other (income) expense

           

MT-001 external research and development costs (1)

     6,406      $ 3,706      $ 26,646      $ 3,706  

MT-002 external research and development costs (2)

     8,680        1,237        17,018        1,237  

MT-003 external research and development costs (3)

     1,401        —         1,401        —   

MT-004 external research and development costs (4)

     6,341        —         6,341        —   

MT-005 external research and development costs (5)

     3,936        —         3,936        —   

Program enablement research and development costs (6)

     —         1,083        —         1,083  

Professional and consulting fees (7)

     1,495        490        3,298        536  

Personnel-related costs

     2,042        8        2,059        8  

Related party stock-based compensation expense

     742        75        1,062        75  

Related party interest expense

     1,515        —         2,223        —   

Other segment items (8)

     167        36        249        36  

Interest income

     (483 )       (29 )       (1,237 )       (29 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ 32,242      $ 6,606      $ 62,996      $ 6,652  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1)

Includes related party amount of $3.6 million and $10.2 million for the three and nine months ended September 30, 2026, respectively, and $3.7 million and $3.7 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively (see Note 13).

(2)

Includes related party amount of $1.0 million and $7.5 million for the three and nine months ended September 30, 2026, respectively and $1.2 million and $1.2 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively.

(3)

Includes related party amount of $1.4 million and $1.4 million for the three and nine months ended September 30, 2026, respectively

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-18


(4)

Includes related party amount of $6.3 million and $6.3 million for the three and nine months ended September 30, 2026, respectively

(5)

Includes related party amount of $3.9 million and $3.9 million for the three and nine months ended September 30, 2026, respectively

(6)

Includes related party amount of $1.1 million and $1.1 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively.

(7)

Includes related party amount of $0.3 million and $0.8 million for the three and nine months ended September 30, 2026, respectively and $0.4 million and $0.4 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025, respectively.

(8)

Includes information technology supplies, travel related expenses and capital-based taxes of $0.2 million for the three and nine months ended September 30, 2026, and less than $0.1 million for the three months ended September 30, 2025 and for the period from June 13, 2025 (inception) to September 30, 2025.

15. Subsequent Events

The Company has evaluated events and transactions occurring subsequent to September 30, 2026 through November 16, 2026, the date at which the unaudited condensed consolidated financial statements were issued.

Reverse Recapitalization and Pre-Closing Financing

On November 6, 2026, the Company completed the Merger with InMed in accordance with the terms of the Merger Agreement, pursuant to which First Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of InMed and the surviving corporation of the First Merger. Immediately following the First Merger and as part of the same overall transaction, the Company merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. Second Merger Sub changed its name to “Mentari Therapeutics Operating Company LLC” and InMed changed its name to “Mentari Therapeutics, Inc.” The Combined Company is led by pre-Merger Mentari’s management team and remains focused on developing therapies for migraine prevention.

In accordance with an exchange ratio determined pursuant to the Merger Agreement (the “Exchange Ratio”), at the effective time of the First Merger, (i) each then-outstanding share of pre-Merger Mentari common stock, including shares issued in connection with the Mentari Pre-Closing Financing, was converted into the right to receive a number of shares of InMed common stock equal to the Exchange Ratio, (ii) each then-outstanding share of Mentari Series Seed preferred stock was converted into the right to receive a number of shares of newly designated InMed Series A non-voting preferred stock, each convertible into 1,000 shares of InMed common stock, equal to the Exchange Ratio divided by 1,000, (iii) each then-outstanding share of Mentari Series A preferred stock was converted into the right to receive shares of InMed common stock based on the Exchange Ratio or, as applicable, pre-funded warrants to purchase InMed common stock, (iv) each then-outstanding option to purchase Mentari common stock was assumed by InMed and converted into an option to purchase shares of InMed common stock, adjusted for the Exchange Ratio, (v) each then-outstanding warrant to purchase Mentari common stock was assumed by InMed and converted into a warrant to purchase shares of InMed common stock, adjusted for the Exchange Ratio, (vi) each then-outstanding share of Mentari restricted stock was assumed by InMed, subject to adjustment pursuant to the Merger Agreement, and (vii) each then-outstanding pre-funded warrant to purchase Mentari common stock was converted into a pre-funded warrant to purchase InMed common stock, subject to adjustment pursuant to the Merger Agreement and the applicable warrant terms. In addition, the vesting of outstanding InMed stock options was accelerated, with in-the-money options cancelled in exchange for shares of InMed common stock and out-of-the-money options cancelled for no consideration.

In connection with the Mentari Pre-Closing Financing, immediately prior to the completion of the Merger, and to provide Mentari with additional capital for its development programs, Pre-Merger Mentari issued and sold shares of common stock and pre-funded warrants to certain new and existing investors for aggregate gross proceeds of approximately $490.0 million. The financing consisted of two separate closings: (i) the First Pre-Closing Financing, pursuant to which investors purchased 147,334,291 shares of Pre-Merger Mentari common stock and 5,875,395 pre-funded warrants at a purchase price of $1.8928 per share and $1.8927 per warrant, respectively, for approximately $290.0 million, including approximately

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-19


$52.7 million of principal and accrued interest under the Convertible Note, which was contributed as consideration in the First Pre-Closing Financing; and (ii) the Second Pre-Closing Financing, pursuant to which investors purchased an additional 67,707,887 shares of common stock and 1,441,933 pre-funded warrants at a purchase price of $2.8923 per share and $2.8922 per warrant, respectively, for approximately $200.0 million. At the closing of the Merger, based on the Exchange Ratio of 0.20065, which gives effect to the Reverse Stock Split, Pre-Merger Mentari common stock and pre-funded warrants subscribed for were converted into the right to receive 29,562,623 shares of common stock and 1,178,898 pre-funded warrants from the First Pre-Closing Financing and the right to receive 13,585,590 shares of common stock and 289,324 pre-funded warrants from the Second Pre-Closing Financing. Shares of Pre-Merger Mentari common stock and pre-funded warrants to purchase Mentari common stock issued pursuant to the Securities Purchase Agreement were converted into shares of InMed common stock and pre-funded warrants to purchase shares of InMed common stock at the closing of the Merger pursuant to the Merger Agreement.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-20

Exhibit 99.2

MENTARI’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

On November 6, 2026, Indigo Merger Sub Corp. (“First Merger Sub”) merged with and into Mentari Therapeutics, Inc. (“Pre-Merger Mentari”), with Pre-Merger Mentari continuing as a wholly owned subsidiary of InMed Pharmaceuticals Inc. (“InMed”) and the surviving corporation of the merger (the “First Merger”). Immediately following the First Merger, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC (“Second Merger Sub”), with Second Merger Sub being the surviving entity of the merger (the “Second Merger” and, together with the First Merger, the “Merger”). In connection with the completion of the Merger, Second Merger Sub changed its name to “Mentari Therapeutics Operating Company LLC” and InMed changed its name to “Mentari Therapeutics, Inc.” (the “Company”).

You should read the following discussion of Mentari’s financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included in InMed’s definitive proxy statement/prospectus filed on Form S-4, most recently amended on September 29, 2026 and declared effective on October 1, 2026 (the “Proxy Statement/Prospectus”), which were incorporated by reference into Mentari Therapeutics, Inc.’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 10, 2026 (the “Current Report on Form 8-K”). The following discussion contains forward-looking statements that reflect our current plans, forecasts, estimates and beliefs and involve risks and uncertainties. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. Our actual results, outcomes and the timing of events could differ materially from those discussed in the forward-looking statements. Forward-looking statements are not historical facts, reflect our current views with respect to future events, and apply only as of the date made. We do not intend, and undertake no obligation, to update these forward-looking statements, except as required by law. References to “we,” “us,” “our” and “the Company” refer to Mentari Therapeutics, Inc. (formerly InMed) and its consolidated subsidiaries after the Merger, and references to “Mentari” refer to Pre-Merger Mentari for periods prior to the Merger and to the Company for periods after the Merger, in each case unless context otherwise requires.

Overview

Mentari is a clinical-stage biotechnology company that intends to become a leader in migraine treatment through the development of a portfolio of preventive migraine therapies. Mentari’s initial product candidates are proprietary monoclonal antibodies that are being designed to address clinically validated migraine targets while also being designed to improve patient convenience through periodic subcutaneous injections. MT-001 is a half life extended antibody that is designed to target pituitary adenylate cyclase-activating polypeptide (“PACAP”), an emerging anti-migraine target that functions independently of calcitonin gene-related peptide (“CGRP”), which is the backbone of several approved therapies. MT-001 is designed to be administered through a convenient, infrequent subcutaneous injection. In mid-2026, Mentari filed a Clinical Trial Application (“CTA”) in New Zealand for MT-001, and MT-001 is now in Phase 1 development, with dosing ongoing and initial data expected in mid-2027. In parallel, Mentari is also developing MT-002, a bispecific antibody designed to simultaneously target PACAP and CGRP, providing the potential to address both known drivers of migraine with a single product candidate. Mentari anticipates filing an Investigational New Drug application (“IND”) in the United States or a CTA for MT-002 in the first quarter of 2027, with initial data expected by year-end 2027.

It is estimated that up to fifteen percent of the world’s population suffers from migraine. An estimated one percent of the population experiences more than eight migraine attacks a month. Although there are multiple drugs approved to treat or to prevent migraine, there remains a significant need for superior therapies. Between forty and fifty percent of patients treated with approved therapies do not achieve a fifty percent reduction in monthly migraine days (“MMDs”). Even those who do experience a reduction in MMDs continue to be burdened by recurrent attacks.

The underlying causes of migraine are not well understood, but a portion of the disease pathology has been shown to be driven by the release of CGRP, which leads to local vasodilation and neuroinflammation. Anti-CGRP therapies are the most recent class of approved therapies, reaching $6 billion in worldwide revenue in 2025. Not all patients respond to anti-CGRP therapies, and many discontinue treatment.


PACAP has recently emerged as an alternative migraine target that functions independently of CGRP. Phase 2 clinical trial results generated with Lu AG09222, in development by H. Lundbeck A/S (“Lundbeck”), show a reduction in MMDs roughly equivalent to that observed with approved anti-CGRP therapies. Mentari believes that anti-PACAP therapies have the potential to meaningfully improve outcomes for patients with migraine who do not experience an adequate reduction in MMDs under existing anti-CGRP therapies.

MT-001 is a product candidate that is being designed to target PACAP, while being administered through a convenient subcutaneous injection instead of monthly intravenous infusions. In preclinical in vitro assays, MT-001 demonstrated potency similar to a reference antibody that was generated by Paragon Therapeutics based on publicly available information about the properties or attributes of Lu AG09222. The reference antibody is not the same compound as Lu AG09222 and may differ from Lu AG09222 in its formulation, manufacturing process or other characteristics. Mentari has not conducted head-to-head trials comparing MT-001 to Lu AG09222. Lu AG09222 has not been approved by the FDA or any other regulatory body. MT-001 was engineered to have both an extended half-life and physiochemical properties to enable subcutaneous administration. Based on preclinical pharmacokinetic data, Mentari projects that a once per four-week or eight-week subcutaneous dose of MT-001 may achieve exposure levels similar to or greater than the exposure of Lu AG09222 reported after intravenous administration in humans. This projection is based, in part, on a three-fold increase in half-life observed in non-human primates (“NHPs”) with MT-001 compared with the Lu AG09222 reference antibody. However, there can be no assurance that MT-001 will achieve similar results in humans. In mid-2026, Mentari filed a CTA in New Zealand for MT-001, and the Phase 1 clinical trial of MT-001 is ongoing.

MT-002 is a bispecific product candidate that is designed to inhibit PACAP and CGRP. Both PACAP and CGRP have been shown to induce migraine through activation of independent sets of receptors. Mentari believes MT-002 has the potential to benefit a broader set of patients than products that only address one of these targets. MT-002 was engineered to be delivered as an infrequent subcutaneous dose and, based on preclinical pharmacokinetic and pharmacodynamic data, Mentari projects that MT-002 may achieve exposure levels similar to or greater than the exposures reported in clinical trials for Lu AG09222 and anti-CGRP antibodies. However, there can be no assurance that MT-002 will achieve similar results in humans. Mentari intends to initially develop MT-002 for the prevention of migraine in people who do not respond to existing anti-CGRP therapies and those who do not experience an adequate reduction in MMDs. Mentari believes that the increased drug activity potentially achievable by simultaneously targeting PACAP and CGRP presents an opportunity for MT-002 to be considered for first-line therapy for migraine prevention. Mentari anticipates filing an IND in the United States or a CTA for MT-002 in the first quarter of 2027.

MT-003, a potential product candidate for which Mentari has the exclusive option to license certain intellectual property rights pursuant to the Paragon Therapeutics Option Agreement, is being designed as a half-life extended anti-CGRP antibody. Although several anti-CGRP products have been approved by the FDA, none can be administered quarterly as a single subcutaneous dose. The only products approved for quarterly dosing are administered either as a quarterly intravenous infusion or as a series of three consecutive subcutaneous injections. Mentari believes that the improved properties and half-life that MT-003 is being designed to achieve may allow it to compete effectively in the anti-CGRP market if successfully developed and approved.

Since Mentari’s inception in June 2025, it has devoted substantially all of its resources to raising capital, organizing the Company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties, and providing general and administrative support for these operations. Mentari does not have any programs approved for sale and has not generated any revenue from product sales. To date, Mentari has funded its operations primarily with proceeds from the issuance of its Series Seed convertible preferred stock, Series A convertible preferred stock, and a Convertible Note. On June 13, 2025, Mentari received gross proceeds of $0.2 million from the issuance of its Series Seed convertible preferred stock and on September 18, 2025, Mentari received gross proceeds of $55.0 million from the issuance of the Series A convertible preferred stock. On May 19, 2026, Mentari received gross proceeds of $50.0 million from the issuance of a Convertible Note.


Mentari has incurred significant operating losses and negative cash flows from operations since inception. Mentari’s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Mentari may develop. Mentari generated net losses of $32.2 million and $63.0 million for the three and nine months ended September 30, 2026, respectively, and $6.6 million and $6.7 million for the three months ended September 30, 2025 and period from June 13, 2025 (inception) to September 30, 2025, respectively. As of September 30, 2026, Mentari had an accumulated deficit of $82.4 million. Mentari expects to continue to incur significantly increased expenses for the foreseeable future if and as it:

 

  •  

advances its existing and future research and development of its MT-001, MT-002, MT-003, MT-004 and MT-005 programs;

 

  •  

seeks and identifies additional research programs and product candidates and initiates discovery-related activities and preclinical studies for those programs;

 

  •  

completes future preclinical studies for its pipeline;

 

  •  

pursues investigational new drug applications or comparable foreign applications that allow commencement of Mentari’s planned clinical trials or future clinical trials for any programs Mentari may develop;

 

  •  

initiates enrollment and successfully completes clinical trials;

 

  •  

pursues positive results from Mentari’s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;

 

  •  

hires research and development, clinical, manufacturing and commercial personnel;

 

  •  

adds operational, financial and management information systems and personnel;

 

  •  

experiences any delays, challenges, or other issues associated with the preclinical and clinical development of Mentari’s programs, including with respect to its regulatory strategies;

 

  •  

develops, maintains and enhances a sustainable, scalable, reproducible and transferable clinical and commercial-scale capabilities through a third-party or Mentari’s own manufacturing facility for the programs Mentari may develop;

 

  •  

seeks, obtains and maintains regulatory approvals for any product candidates for which Mentari successfully completes clinical trials;

 

  •  

ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which Mentari may obtain regulatory approval;

 

  •  

maintains, expands, enforces, defends and protects Mentari’s intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products Mentari may develop and defends any intellectual property-related claims;

 

  •  

further acquires or in-licenses product candidates or programs, intellectual property and technologies;

 

  •  

maintains Mentari’s current agreement with Paragon and establishes and maintains any future collaborations, including making milestone, royalty or other payments thereunder; and

 

  •  

incurs additional costs of operating as a public company, including increased costs of audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs.

Any changes in the outcome of any of these variables with respect to the development of programs that Mentari may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the U.S. Food and Drug Administration or another comparable regulatory authority were to require Mentari to conduct clinical trials beyond those that Mentari currently anticipates will be required to


complete clinical development and obtain regulatory approval of one or more product candidates, or if Mentari’s experiences significant delays in Mentari’s preclinical studies or clinical trials, Mentari would be required to expend significant additional financial resources and time on the completion of clinical development. Mentari may never obtain regulatory approval for any of its product candidates.

Mentari will not generate revenue from product sales unless and until it successfully initiates and completes clinical development and obtains regulatory approval for any product candidates. If Mentari obtains regulatory approval for any of its product candidates and does not enter into a commercialization partnership, it expects to incur significant expenses related to developing Mentari’s commercialization capability to support product sales, manufacturing, marketing, and distribution.

Based on its current operating plan, Mentari has concluded its existing cash and cash equivalents as of September 30, 2026 of $45.8 million, combined with the proceeds from the Merger and the Mentari Pre-Closing Financing (as defined in “Recent Developments” below) will be sufficient to fund its operating plan for at least 12 months after the date Mentari’s financial statements for the period ended September 30, 2026 are issued.

Recent Developments

The Merger and Pre-Closing Financing

On May 19, 2026, Mentari and InMed entered into a Merger Agreement, which was subsequently amended on July 6, 2026 (as amended, the “Merger Agreement”), subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. On November 6, 2026, Mentari completed the Merger with InMed in accordance with the terms of the Merger Agreement. The combined company is led by Mentari’s management team and remains focused on developing therapies for migraine prevention.

Immediately prior to the completion of the Merger, and to provide Mentari with additional capital for its development programs, Pre-Merger Mentari issued and sold to certain new and existing investors an aggregate of 215,042,178 shares of common stock and 7,317,328 pre-funded warrants, exercisable for an equivalent number of shares of Pre-Merger Mentari common stock, for aggregate gross proceeds of approximately $490.0 million (the “Mentari Pre-Closing Financing,” and together with the Merger, the “Transactions”). The Mentari Pre-Closing Financing consisted of two separate financings totaling approximately $290.0 million and $200.0 million, respectively, including approximately $52.7 million of principal and accrued interest under the Convertible Note issued in May 2026.

In accordance with an exchange ratio determined pursuant to the Merger Agreement (the “Exchange Ratio”), at the effective time of the First Merger (the “First Effective Time”), (i) each then-outstanding share of Pre-Merger Mentari common stock, including shares issued in connection with the Mentari Pre-Closing Financing, was converted into the right to receive shares of InMed common stock based on the Exchange Ratio, (ii) each then-outstanding share of Pre-Merger Mentari Series Seed Preferred Stock was converted into the right to receive shares of newly designated InMed Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”), at a ratio equal to the Exchange Ratio divided by 1,000, with each share convertible into 1,000 shares of InMed common stock, (iii) each then-outstanding share of Pre-Merger Mentari Series A Preferred Stock was converted into the right to receive shares of InMed common stock or, as applicable, pre-funded warrants, based on the Exchange Ratio, (iv) each then-outstanding option and warrant to purchase Pre-Merger Mentari common stock was assumed by InMed and converted into an option or warrant to purchase InMed common stock, adjusted for the Exchange Ratio, (v) each then-outstanding share of Pre-Merger Mentari restricted stock was assumed by InMed, subject to adjustment under the Merger Agreement, and (vi) each then-outstanding pre-funded warrant to purchase Pre-Merger Mentari common stock was converted into a pre-funded warrant to purchase InMed common stock, subject to the Exchange Ratio and applicable warrant terms. In addition, outstanding InMed stock options were accelerated, with in-the-money options cancelled in exchange for shares of InMed common stock and out-of-the-money options cancelled for no consideration.


The Exchange Ratio is calculated as 0.20065 shares of InMed common stock for each share of Pre-Merger Mentari common stock or Pre-Merger Mentari Series A Preferred Stock (and 0.00020065 shares of Series A Non- Voting Preferred Stock for each share of Pre-Merger Mentari Series Seed Preferred Stock) on the Closing Date, which gives effect to the one-for-ten reverse stock split of InMed common shares effected on November 4, 2026. Following the closing of the Merger, former Mentari securityholders, including investors in the Mentari Pre-Closing Financing, own approximately 99.0% of the outstanding capital stock of the Company on a fully diluted basis, while former InMed securityholders own approximately 1.0%. Of the Company’s outstanding capital stock, approximately 25.7% is attributable to former Mentari securityholders, excluding the Mentari Pre-Closing Financing, and approximately 73.4% is attributable to shares and pre-funded warrants issued in the Mentari Pre-Closing Financing. These ownership percentages reflect (a) InMed’s estimated Net Cash (as defined in the Merger Agreement) of approximately $(4.4) million at closing, (b) the Mentari Pre-Closing Financing for aggregate gross proceeds of approximately $490.0 million, including approximately $52.7 million of principal and accrued interest under the Convertible Note, (c) a valuation for InMed of $5.6 million, and (d) a valuation for Mentari of $125.0 million plus $290.0 million of assumed proceeds from the First Pre-Closing Financing, in each case as further described in the Merger Agreement.

At the closing of the Merger, based on the Exchange Ratio, the 43,148,213 shares of Mentari common stock and 1,468,222 pre-funded warrants issued pursuant to the Mentari Pre-Closing Financing were converted into the right to receive shares of common stock of the Company and pre-funded warrants to purchase shares of common stock of the Company, respectively, in accordance with the terms of the Merger Agreement. The Mentari Pre-Closing Financing generated aggregate gross proceeds of approximately $490.0 million, consisting of $290.0 million from the First Pre-Closing Financing, including approximately $52.7 million of principal and accrued interest under the Convertible Note, and $200.0 million from the Second Pre-Closing Financing.

Impact of General Economic Risk Factors on Mentari’s Operations

Uncertainty in the global economy presents significant risks to Mentari’s business. Mentari is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While Mentari is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of Mentari’s business, including the impacts on participants in any future clinical trials and its employees, suppliers, vendors and business partners and Mentari’s future access to capital, the ultimate extent of the impact on Mentari’s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Mentari’s control and could exist for an extended period of time. Mentari will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources. For additional information, see the section titled “Risk Factors—Risks Related to Mentari” in the Proxy Statement/Prospectus.

Components of Results of Operations

Revenue

To date, Mentari has not generated revenue from any sources, including product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future. If Mentari’s development efforts for its product candidates are successful and result in regulatory approval, Mentari may generate revenue in the future from product sales or payments from future collaboration or license agreements that Mentari may enter into with third parties, or any combination thereof. Mentari cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product candidates. Mentari may never succeed in obtaining regulatory approval for any of its product candidates.


Operating Expenses

Mentari’s operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.

Research and Development

Research and development expenses consist primarily of costs incurred in connection with the research and development of Mentari’s programs. These expenses include:

 

  •  

costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Mentari’s behalf and services rendered under the Paragon Option Agreement for MT-001, MT-002, MT-003, MT-004 and MT-005;

 

  •  

expenses incurred in connection with continuing Mentari’s current research programs and discovery-phase development of any programs Mentari may identify, including under future agreements with third parties, such as consultants and contractors; and

 

  •  

personnel-related expenses including recruiting costs, salaries, bonuses, benefits and stock-based compensation expense.

Mentari expenses research and development costs as incurred. For the three and nine months ended September 30, 2026 and for three months ended September 30, 2025 and period from June 13, 2025 (inception) to September 30, 2025, Mentari recognized $16.9 million, $30.5 million, $6.1 million and $6.1 million, respectively, of research and development expenses in Mentari’s unaudited condensed consolidated statements of operations and comprehensive loss in connection with services provided under the Paragon Option Agreement.

Mentari expects its research and development expenses to increase substantially for the foreseeable future as Mentari continues to invest in research and development activities related to the continued development of Mentari’s programs and developing any potential future programs, as well as advancing manufacturing and conducting clinical trials for both existing and future programs.

General and Administrative

General and administrative expenses consist of personnel-related expenses including recruiting costs, salaries, bonuses, benefits and stock-based compensation. Other significant general and administrative expenses include professional and consulting fees associated with accounting, audit, tax and investor and public relations, legal fees relating to corporate matters and patent-related activities, insurance costs, information technology.

Mentari expects that its general and administrative expenses will increase substantially for the foreseeable future as Mentari increases its headcount. Mentari also expects to incur increased expenses associated with becoming a public company, including transactional costs and increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Mentari also expects to incur additional intellectual property-related expenses as Mentari files patent applications to protect innovations arising from its research and development activities.

Other Income (Expense), net

Other income (expense), net consists of interest income of $0.5 million, $1.2 million and less than $0.1 million earned on Mentari’s money market account for the three and nine months ended September 30, 2026 and three months ended September 30, 2025 and period from June 13, 2025 (inception) to September 30, 2025, respectively, and related party interest expense of $1.5 million and $2.2 million incurred for the three and nine months ended September 30, 2026, respectively, relating to Mentari’s outstanding Convertible Note.


Income Taxes

No provision for income taxes was recorded for the three and nine months ended September 30, 2026 and three months ended September 30, 2025 and period from June 13, 2025 (inception) to September 30, 2025. Mentari has recorded a full valuation allowance against its net deferred tax assets at each balance sheet date, as Mentari believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date and expectation of future losses.

Results of Operations for the Three Months Ended September 30, 2026 and the Three Months Ended September 30, 2025

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
 

Operating expenses

     

Research and development (1)

   $ 28,442      $ 6,101  

General and administrative (2)

     2,768        534  
  

 

 

    

 

 

 

Total operating expenses

     31,210        6,635  
  

 

 

    

 

 

 

Loss from operations

     (31,210 )       (6,635 ) 
  

 

 

    

 

 

 

Other income (expense):

     

Interest income

     483        29  

Interest expense (3)

     (1,515 )       —   
  

 

 

    

 

 

 

Total other income (expense), net

     (1,032 )       29  
  

 

 

    

 

 

 

Net loss and comprehensive loss

     (32,242 )       (6,606 ) 
  

 

 

    

 

 

 

The following table summarizes Mentari’s unaudited condensed consolidated statements of operations and comprehensive loss for the periods presented (in thousands):

 

(1)

Includes related party amount of $16.9 million for the three months ended September 30, 2026 and $6.1 million for the three months ended September 30, 2025.

 

(2)

Includes related party amount of $0.3 million for the three months ended September 30, 2026 and $0.4 million for the three months ended September 30, 2025.

 

(3)

Includes related party amount of $1.5 million for the three months ended September 30, 2026 and $0 for the three months ended September 30, 2025.


Research and Development Expenses

The following table summarizes Mentari’s research and development expenses incurred for the periods presented (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
 

External research and development costs by selected target:

     

MT-001 (1)

   $ 6,406      $  3,706  

MT-002 (2)

     8,680        1,237  

MT-003 (3)

     1,401        —   

MT-004 (4)

     6,341        —   

MT-005 (5)

     3,936        —   

Program enablement (6)

     —         1,083  

Other research and development costs:

     

Related party stock-based compensation

     742        75  

Personnel-related costs

     850        —   

Professional and consulting

     38        —   

Other

     48     
  

 

 

    

 

 

 

Total research and development expenses

   $  28,442      $ 6,101  
  

 

 

    

 

 

 

 

(1)

Includes related party amount of $3.6 million for the three months ended September 30, 2026 and $3.7 million for the three months ended September 30, 2025.

(2)

Includes related party amount of $1.0 million for the three months ended September 30, 2026 and $1.2 million for the three months ended September 30, 2025.

(3)

Includes related party amount of $1.4 million for the three months ended September 30, 2026 and $0 for the three months ended September 30, 2025.

(4)

Includes related party amount of $6.3 million for the three months ended September 30, 2026 and $0 for the three months ended September 30, 2025.

(5)

Includes related party amount of $3.9 million for the three months ended September 30, 2026 and $0 for the three months ended September 30, 2025.

(6)

Includes related party amount of $0 for the three months ended September 30, 2026 and $1.1 million for the three months ended September 30, 2025.

Research and development expenses were $28.4 million for the three months ended September 30, 2026 and consisted primarily of the following:

 

  •  

$2.8 million of research and development expense related to chemistry, manufacturing, and development costs for MT-001;

 

  •  

$3.6 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-001;

 

  •  

$7.7 million of research and development expense related to chemistry, manufacturing, and development costs for MT-002;

 

  •  

$1.0 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-002;

 

  •  

$1.4 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-003;

 

  •  

$6.3 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-004;

 

  •  

$3.9 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-005; and


  •  

$1.7 million of other research and development costs, including stock-based compensation, personnel-related costs, professional and consulting fees, and other expenses.

Research and development expenses were $6.1 million for the three months ended September 30, 2025, and consisted primarily of the following:

 

  •  

$3.7 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-001;

 

  •  

$1.2 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-002;

 

  •  

$1.1 million of research and development expense due to Paragon for program-enablement expenses; and

 

  •  

$0.1 million of personnel-related costs, including related party stock-based compensation expense.

General and Administrative Expenses

The following table summarizes Mentari’s total general and administrative expenses for the periods presented (in thousands):

 

     Three Months Ended
September 30, 2026
     Three Months Ended
September 30, 2025
 

Professional and consulting fees (1)

   $  1,457      $  490  

Personnel-related costs

     1,192        8  

Other

     119        36  
  

 

 

    

 

 

 

Total general and administrative expenses

   $ 2,768      $ 534  
  

 

 

    

 

 

 

 

(1)

Includes related party amount of $0.3 million for the three months ended September 30, 2026 and $0.4 million for the three months ended September 30, 2025.

General and administrative expenses were $2.8 million for the three months ended September 30, 2026 and consisted primarily of the following:

 

  •  

$1.5 million of professional and consulting fees associated with accounting, audit, tax, investor and public relations, and legal fees, including $0.3 million reimbursed to Paragon and Fairmount for such services provided;

 

  •  

$1.2 million of personnel-related costs; and

 

  •  

$0.1 million of other costs including travel, facilities, and tax expenses.

General and administrative expenses were $0.5 million for the three months ended September 30, 2025 and consisted primarily of the following:

 

  •  

$0.5 million of professional and consulting fees associated with accounting, audit, tax, investor and public relations, and legal fees, including $0.4 million reimbursed to Paragon and Fairmount for such services provided;

 

  •  

Less than $0.1 million of personnel-related costs; and

 

  •  

Less than $0.1 million of other costs including travel, facilities, and tax expenses.


Results of Operations for the Nine Months Ended September 30, 2026 and the Period from June 13, 2025 (Inception) to September 30, 2025

The following table summarizes Mentari’s unaudited condensed consolidated statements of operations and comprehensive loss for the periods presented (in thousands):

 

     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

Operating expenses

     

Research and development (1)

   $ 57,709      $ 6,101  

General and administrative (2)

     4,301        580  
  

 

 

    

 

 

 

Total operating expenses

     62,010        6,681  
  

 

 

    

 

 

 

Loss from operations

     (62,010 )       (6,681 ) 
  

 

 

    

 

 

 

Other income (expense):

     

Interest income

     1,237        29  

Interest expense (3)

     (2,223 )       —   
  

 

 

    

 

 

 

Total other income (expense), net

     (986 )       29  
  

 

 

    

 

 

 

Net loss and comprehensive loss

     (62,996 )       (6,652 ) 
  

 

 

    

 

 

 

 

(1)

Includes related party amount of $30.5 million for the nine months ended September 30, 2026 and $6.1 million for the period from June 13, 2025 (inception) to September 30, 2025.

(2)

Includes related party amount of $0.8 million for the nine months ended September 30, 2026 and $0.4 million for the period from June 13, 2025 (inception) to September 30, 2025.

(3)

Includes related party amount of $2.2 million for the nine months ended September 30, 2026 and $0 for the period from June 13, 2025 (inception) to September 30, 2025.

Research and Development Expenses

The following table summarizes Mentari’s research and development expenses incurred for the periods presented (in thousands):

 

     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

External research and development costs by selected target:

     

MT-001 (1)

   $  26,646      $  3,706  

MT-002 (2)

     17,018        1,237  

MT-003 (3)

     1,401        —   

MT-004 (4)

     6,341        —   

MT-005 (5)

     3,936        —   

Program enablement (6)

     —         1,083  

Other research and development costs:

     

Related party stock-based compensation

     1,062        75  

Personnel-related costs

     850        —   

Professional and consulting

     402        —   

Other

     53     
  

 

 

    

 

 

 

Total research and development expenses

   $ 57,709      $ 6,101  
  

 

 

    

 

 

 

 

(1)

Includes related party amount of $10.2 million for the nine months ended September 30, 2026 and $3.7 million for the period from June 13, 2025 (inception) to September 30, 2025.


(2)

Includes related party amount of $7.5 million for the nine months ended September 30, 2026 and $1.2 million for the period from June 13, 2025 (inception) to September 30, 2025.

(3)

Includes related party amount of $1.4 million for the nine months ended September 30, 2026 and $0 for the period from June 13, 2025 (inception) to September 30, 2025.

(4)

Includes related party amount of $6.3 million for the nine months ended September 30, 2026 and $0 for the period from June 13, 2025 (inception) to September 30, 2025.

(5)

Includes related party amount of $3.9 million for the nine months ended September 30, 2026 and $0 for the period from June 13, 2025 (inception) to September 30, 2025.

(6)

Includes related party amount of $0 for the nine months ended September 30, 2026 and $1.1 million for the period from June 13, 2025 (inception) to September 30, 2025.

Research and development expenses were $57.7 million for the nine months ended September 30, 2026 and consisted primarily of the following:

 

  •  

$16.5 million of research and development expense related to chemistry, manufacturing, and development costs for MT-001;

 

  •  

$10.2 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-001;

 

  •  

$7.5 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-002;

 

  •  

$9.5 million of research and development expense related to chemistry, manufacturing, and development costs for MT-002;

 

  •  

$1.4 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-003;

 

  •  

$6.3 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-004;

 

  •  

$3.9 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for MT-005;

 

  •  

$2.4 million of other research and development costs, including stock-based compensation, personnel-related costs, professional and consulting fees, and other expenses.

General and Administrative Expenses

The following table summarizes Mentari’s total general and administrative expenses for the period presented (in thousands):

 

     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

Professional and consulting fees (1)

   $  2,896      $  536  

Personnel-related costs

     1,209        8  

Other

     196        36  
  

 

 

    

 

 

 

Total general and administrative expenses

   $ 4,301      $ 580  
  

 

 

    

 

 

 

 

(1)

Includes related party amount of $0.8 million for the nine months ended September 30, 2026 and $0.4 million for period from June 13, 2025 (inception) to September 30, 2025.

General and administrative expenses were $4.3 million for the nine months ended September 30, 2026 and consisted primarily of the following:

 

  •  

$2.9 million of professional and consulting fees associated with accounting, audit, tax, investor and public relations, and legal fees, including $0.8 million reimbursed to Paragon and Fairmount for such services provided;


  •  

$1.2 million of personnel-related costs; and

 

  •  

$0.2 million of other costs including travel, facilities, and tax expenses.

General and administrative expenses were $0.5 million for the period from June 13, 2025 (inception) to September 30, 2025 and consisted primarily of the following:

 

  •  

$0.5 million of professional, consulting, and legal fees related to the formation of Mentari, including $0.4 million reimbursed to Paragon for services provided;

 

  •  

Less than $0.1 million of personnel-related costs; and

 

  •  

Less than $0.1 million of other general and administrative expenses.

Liquidity and Capital Resources

Sources of Liquidity

Since its inception, Mentari has incurred significant operating losses and negative operating cash flows. Mentari expects to incur significant expenses and operating losses for the foreseeable future as Mentari continues the clinical development of MT-001 and the preclinical development of its other programs, and commences clinical development of MT-002, MT-003, MT-004, and MT-005. Mentari has not yet commercialized any products and Mentari does not expect to generate revenue from sale of products for several years, if at all. To date, Mentari has funded its operations primarily with proceeds from the issuance of its Series Seed convertible preferred stock, Series A convertible preferred stock, and Convertible Note. In June 2025, Mentari received gross proceeds of $0.2 million from the issuance of its Series Seed convertible preferred stock. In September 2025, Mentari received gross proceeds of $55.0 million from the issuance of Series A convertible preferred stock. In May 2026, Mentari received gross proceeds of $50.0 million from the issuance of a Convertible Note and has the right to issue additional convertible notes up to an aggregate principal amount equal to $20.0 million. As of September 30, 2026 and December 31, 2025, Mentari had cash and cash equivalents of $45.8 million and $46.3 million, respectively.

Cash Flows for the Nine Months Ended September 30, 2026 and for the Period from June 13, 2025 (Inception) to September 30, 2025

The following table summarizes Mentari’s cash flows for the periods presented (in thousands):

 

     Nine Months Ended
September 30, 2026
     Period from June 13,
2025 (Inception) to
September 30, 2025
 

Net cash (used in) provided by operating activities

   $ (47,973 )     $ 149  

Net cash provided by financing activities

     47,505        55,130  
  

 

 

    

 

 

 

Net (decrease) increase in cash and cash equivalents

   $ (468)      $ 55,279  
  

 

 

    

 

 

 

Net Cash Used in Operating Activities

For the nine months ended September 30, 2026, net cash used in operating activities was $48.0 million, which was primarily attributable to a net loss of $63.0 million, partially offset by net cash provided by changes in Mentari’s operating assets and liabilities of $13.2 million and non-cash stock-based compensation expense of $1.8 million. The net cash used by changes in Mentari’s operating assets and liabilities of $13.2 million primarily consisted of a $0.5 million increase in accounts payable, $9.1 million increase in accrued expenses, $4.6 million increase in related party accounts payable and accrued expenses, and $2.2 million increase in related party accrued interest payable, partially offset by $3.4 million increase in prepaid expenses and other current assets. The increase in operating assets and liabilities was primarily due to an overall increase in business activity.


For the period from June 13, 2025 (inception) to September 30, 2025, net cash provided by operating activities was $0.1 million, which was primarily attributable to a net loss of $6.7 million, offset by net cash provided by changes in Mentari’s operating liabilities of $6.8 million. The net cash provided by changes in Mentari’s operating liabilities primarily consisted of a $0.2 million increase in accounts payable, $0.1 million increase in accrued expenses, and $6.5 million increase in related party accounts payable and accrued expenses. The increase in operating liabilities was primarily due to an overall increase in business activity.

Net Cash Provided by Financing Activities

For the nine months ended September 30, 2026, net cash provided by financing activities was $47.5 million primarily from $50.0 million of net proceeds from the issuance of a note payable to a related party, partially offset by $2.5 million of deferred offering costs paid.

For the period from June 13, 2025 (inception) to September 30, 2025, net cash provided by financing activities was $55.1 million consisting primarily of net proceeds from the issuance of Series A convertible preferred stock of $54.9 million and net proceeds from the issuance of Series Seed convertible preferred stock of $0.2 million.

Future Funding Requirements

To date, Mentari has not generated any revenue from product sales. Mentari does not expect to generate revenue from product sales unless and until Mentari successfully completes preclinical and clinical development of, receives regulatory approval for, and commercializes a product candidate. Mentari does not know when, or if, that will occur. Mentari expects its expenses to increase substantially in connection with its ongoing activities, particularly as Mentari continues preclinical activities and studies and initiates clinical trials. In addition, if Mentari obtains regulatory approval for any programs, Mentari expects to incur significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, Mentari expects to incur additional costs associated with operating as a public company. The timing and amount of Mentari’s operating expenditures will depend largely on the factors set out above.

Mentari’s funding requirements and timing and amount of its operating expenditures will depend on many factors, including, but not limited to:

 

  •  

the rate of progress in the development of Mentari’s existing and future research and development activities;

 

  •  

the scope, progress, results and costs of additional research programs and product candidates and discovery-related activities and preclinical studies for those programs;

 

  •  

the ability of Mentari to successfully file investigational new drug applications or comparable foreign applications and obtain authorization to commence Mentari’s planned clinical trials or future clinical trials for any programs Mentari may develop;

 

  •  

the costs of enrollment and successful completion of clinical trials;

 

  •  

the costs necessary to pursue positive results from Mentari’s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;

 

  •  

the costs of hiring research and development, clinical, manufacturing and commercial personnel;

 

  •  

the costs of adding operational, financial, legal, and information technology systems and personnel;


  •  

the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;

 

  •  

the costs of developing, maintaining and enhancing sustainable, scalable, reproducible and transferable clinical and commercial-scale cGMP capabilities through a third-party or Mentari’s own manufacturing facility for the programs Mentari may develop;

 

  •  

the costs and timing of future commercialization activities, including establishing sales, marketing and distribution infrastructure to commercialize any programs, for any of Mentari’s product candidates for which Mentari receives regulatory approval;

 

  •  

the revenue, if any, received from commercial sales of Mentari’s product candidates for which Mentari receives marketing approval;

 

  •  

the costs and timing of preparing, maintaining, expanding, enforcing, defending and protecting Mentari’s intellectual property rights and protection or regulatory exclusivity for any products Mentari may develop and defending any intellectual property-related claims;

 

  •  

the timing and payment of milestone, royalty or other payments Mentari must make pursuant to its existing and potential future collaborations and licensing arrangements with third parties;

 

  •  

the costs Mentari incurs in maintaining business operations;

 

  •  

the costs associated with being a public company, including costs of audit, legal, regulatory and tax- related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs;

 

  •  

the effect of competing technological and market developments; and

 

  •  

the extent to which Mentari acquires or invests in businesses, products and technologies, including entering into licensing or collaboration arrangements for programs.

Identifying potential programs and product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and Mentari may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Mentari’s programs, if approved, may not achieve commercial success. Mentari’s commercial revenues, if any, will be derived from sales of products that Mentari does not expect to be commercially available for many years, if ever. Accordingly, Mentari will need to obtain substantial additional funds to achieve its business objectives.

Adequate additional funds may not be available to Mentari on acceptable terms, or at all. To the extent that Mentari raises additional capital through the sale of equity or convertible debt securities, ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Mentari’s existing stockholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Mentari’s ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute ownership interests.


If Mentari raises additional funds through strategic collaborations or licensing arrangements with third parties, Mentari may have to relinquish valuable rights to its technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to Mentari. If Mentari is unable to raise additional funds through equity or debt financings when needed, Mentari may be required to delay, limit or terminate its product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that Mentari would otherwise prefer to develop and market itself.

As of September 30, 2026, Mentari had cash and cash equivalents of $45.8 million. Mentari expects that the existing cash and cash equivalents, which was primarily raised from Series Seed and Series A convertible preferred stock financings and Convertible Note financing, together with the proceeds from the Merger and Mentari’s Pre-Closing Financing, will be sufficient to fund Mentari’s operating plans for at least twelve months from the date the financial statements for the period ended September 30, 2026 are issued. Mentari estimates that its existing cash and cash equivalents as of September 30, 2026, together with the net proceeds from the Merger and the Mentari Pre-Closing Financing, will be sufficient to enable Mentari to fund Mentari’s operating expenses and capital expenditure requirements into 2029. Mentari has based this estimate on assumptions that may prove to be wrong, Mentari’s operating plan may change as a result of many factors currently unknown to Mentari and Mentari could exhaust its available capital resources sooner than Mentari expects.

Contractual Obligations and Commitments

Mentari enters into contracts in the normal course of business with CROs, CMOs, and with other vendors for preclinical research studies, clinical trials, manufacturing, and other services and products for operating purposes. These contracts generally provide for termination on notice or may have a potential termination fee if the contract is cancelled within a specified time, and therefore, are cancellable contracts. Mentari does not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of September 30, 2026.

See Notes 5 and 10 to the condensed consolidated financial statements included as Exhibit 99.1 to this Current Report on Form 8-K for further information regarding the Company’s contractual debt obligations and commitments under its Option and License Agreements.

Critical Accounting Policies and Significant Judgments and Estimates

Mentari’s management’s discussion and analysis of its financial condition and results of operations is based on Mentari’s financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Mentari bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from these estimates or assumptions.

Mentari’s significant accounting policies are described in more detail in Note 2 to its audited financial statements as of and for the year ended December 31, 2025 and for the period from June 13, 2025 (inception) to December 31, 2025, included in the Registration Statement on Form S-4, most recently amended on September 29, 2026 and declared effective on October 1, 2026. Since the date of those financial statements, there have been no material changes to Mentari’s significant accounting policies, except as described in the notes to Mentari’s condensed financial statements for the three and nine months ended September 30, 2026 included as Exhibit 99.1 to this Current Report on Form 8-K. Mentari believes the following accounting policies used in the preparation of its financial statements require the most significant judgments and estimates.

Research and Development Contract Costs Accruals

Mentari records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of Mentari’s research and development expenses, with a substantial portion of Mentari’s ongoing research and development activities conducted by third-party service providers, including Mentari’s related party Paragon, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”).


Mentari accrues for expenses resulting from obligations under the Paragon Option Agreement by and among Mentari, Paragon and Paratari and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to Mentari. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. Mentari makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to Mentari’s accruals could materially affect Mentari’s results of operations. As of September 30, 2026, Mentari has not experienced any material deviations between accrued and actual research and development expenses.

Stock-Based Compensation

Mentari classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Mentari measures stock-based awards granted to employees, directors, and non-employees in the form of stock options and restricted stock awards (“RSAs”). Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if Mentari had paid cash in exchange for the goods or services. Mentari accounts for forfeitures as they occur. Mentari measures stock options based on their fair value on the date of grant using the Black-Scholes option-pricing model. Mentari measures RSAs using the difference, if any, between the purchase price per share of the award and the estimated fair value of Mentari’s common stock at the date of grant.

The Black-Scholes option-pricing model uses inputs that are determined by the board of directors on the date of grant and assumptions Mentari makes for the volatility of stock-based awards, the expected term of stock- based awards, the risk-free interest rate for a period that approximates the expected term of Mentari’s stock-based awards and its expected dividend yield. Mentari has historically been a private company and lacks company-specific historical and implied volatility information of Mentari’s stock. Therefore, Mentari estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of Mentari’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Mentari has estimated a 0% dividend yield based on the expected dividend yield and the fact that Mentari has never paid, and does not expect to pay, any cash dividends in the foreseeable future. See Note 8 to Mentari’s condensed financial statements for the three and nine months ended September 30, 2026, included as Exhibit 99.1 to this Current Report on Form 8-K for information concerning the specific assumptions Mentari used in applying the Black-Scholes option-pricing model to determine the estimated fair value of stock options granted during the periods presented.

Determination of Fair Value of Common Stock

As there has been no public market for Mentari’s stock-based awards to date, the estimated fair value of stock-based awards has been determined by Mentari’s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that it believed were relevant. In addition, Mentari’s board of directors considered various objective and subjective factors to determine the fair value of its share-based awards as of each grant date, including:

 

  •  

the prices at which Mentari sold shares of convertible preferred stock and preferences of the convertible preferred stock relative to its stock-based awards at the time of each grant;


  •  

Mentari’s common stock valuations;

 

  •  

the progress of Mentari’s research and development programs, including the status of discovery-phase studies for its product candidates;

 

  •  

Mentari’s stage of development and business strategy;

 

  •  

external market conditions affecting the biotechnology industry and trends within the biotechnology industry;

 

  •  

Mentari’s financial position, including cash on hand, and its historical and forecasted performance and operating results; and

 

  •  

the lack of an active public market for Mentari’s common stock and its convertible preferred stock on the date of grant.

The Option Pricing Model treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The future value of the common stock is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.

The assumptions underlying these valuations represented management’s best estimate, which involved inherent uncertainties and the application of management’s judgment. As a result, if Mentari had used significantly different assumptions or estimates, the fair value of Mentari’s common stock and its stock-based compensation expense could have been materially different.

Once a public trading market for Mentari’s common stock has been established in connection with the completion of the Merger, it is no longer necessary for Mentari’s board of directors to estimate the fair value of its stock-based awards in connection with its accounting for granted stock-based awards or other such awards Mentari may grant, as the fair value of Mentari’s common stock and share-based awards is determined based on the quoted market price of Mentari’s common stock.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact Mentari’s financial position, results of operations or cash flows is disclosed in Note 2 to Mentari’s condensed financial statements for the three and nine months ended September 30, 2026 included as Exhibit 99.1 to this Current Report on Form 8-K.

Off-Balance Sheet Arrangements

As of September 30, 2026, Mentari did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

As of September 30, 2026, the Convertible Note bears interest until June 2028 at a fixed rate per annum equal to 12%. An immediate 10% change in the prime rate would not have an impact on Mentari’s debt- related obligations, financial position or results of operations. The Convertible Note was settled in connection with the Mentari Pre-Closing Financing and is no longer outstanding.


Inflation Risk

Mentari’s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Mentari believes the effects of inflation, if any, on its business, results of operations and financial condition have been immaterial. Mentari cannot assure you its business will not be affected in the future by inflation.

Filing Exhibits & Attachments

5 documents

Keep reading